NCT02659631 is a Phase 1 clinical trial of PF-06671008 in Neoplasms, sponsored by Pfizer.

Who is sponsoring NCT02659631?

NCT02659631 is sponsored by Pfizer.

What drugs are being tested in NCT02659631?

Interventions in NCT02659631: PF-06671008, PF-06671008.

Is NCT02659631 still recruiting?

NCT02659631 is currently terminated. Last updated 6 May 2020.

Are results published for NCT02659631?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2020-05-06 · How we verify

NCT02659631

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PF-06671008 Dose Escalation Study in Advanced Solid Tumors

Terminated Phase 1 Results posted Last updated 6 May 2020

What this trial tests

Phase 1 trial testing PF-06671008 in Neoplasms in 28 participants. Terminated before completion.

Timeline

28 April 2016

Primary endpoint
29 March 2019

29 March 2019

Quick facts

Lead sponsor	Pfizer
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	28
Start date	28 April 2016
Primary completion	29 March 2019
Estimated completion	29 March 2019
Sites	9 locations across United States

Drugs / interventions tested

PF-06671008 — full drug profile →
PF-06671008 — full drug profile →

Conditions studied

Neoplasms — all drugs for Neoplasms →

Sponsor

Pfizer — full company profile →

Who can join

18 and older, any sex, with Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of Participants With Dose-Limiting Toxicities (DLTs) - Part 1 Primary · Baseline through Day 21 (Cycle 1)

DLT was defined as any of the following adverse events occurring in the first cycle of treatment (21 days after the first dose): a) Hematologic: Febrile neutropenia defined as an absolute neutrophil count (ANC) \<1.0 x 10\^9/L with a single temperature of \>38.3°C, or 101°F, or a sustained temperature of \>=38°C, or 100.4°F, for more than one hour; b) Non-hematologic: Delay by more than 2 weeks in receiving the next scheduled dose due to persisting treatment related toxicities; c) Any grade 3 or 4 clinically-relevant hematologic or non-hematologic toxicity.

Group	Value	95% CI
PF-06671008 1.5 ng/kg IV	0
PF-06671008 7.5 ng/kg IV	0
PF-06671008 20 ng/kg IV	0
PF-06671008 50 ng/kg IV	0
PF-06671008 100 ng/kg IV	0
PF-06671008 200 ng/kg IV	0
PF-06671008 300 ng/kg IV	0
PF-06671008 400 ng/kg IV	1
PF-06671008 200 ng/kg SC	0
PF-06671008 200 ng/kg Prime and 300 ng/kg Maintenance IV	0

Maximum Serum Concentration (Cmax) of PF-06671008 Secondary · C1D1 0, 1, 2, 4, 8, 24, 48, 72 and 96 hrs post-dose, C2D1 0, 2, 4, 8, 24, 48, 72 and 96 hrs post-dose

Maximum serum concentration (Cmax) of PF-06671008 was observed directly from data. Geometric mean was not calculated if fewer than 3 participants had reportable parameter values.

Cycle 1 Day 1

Group	Value	95% CI
PF-06671008 1.5 ng/kg IV	NA	± NA
PF-06671008 7.5 ng/kg IV	NA	± NA
PF-06671008 20 ng/kg IV	0.1926	± 20
PF-06671008 50 ng/kg IV	NA	± NA
PF-06671008 100 ng/kg IV	1.108	± 32
PF-06671008 200 ng/kg IV	2.008	± 33
PF-06671008 300 ng/kg IV	2.387	± 36
PF-06671008 400 ng/kg IV	4.049	± 14
PF-06671008 200 ng/kg SC	NA	± NA
PF-06671008 200 ng/kg Prime and 300 ng/kg Maintenance IV	NA	± NA

Cycle 2 Day 1

Group	Value	95% CI
PF-06671008 1.5 ng/kg IV	NA	± NA
PF-06671008 7.5 ng/kg IV	NA	± NA
PF-06671008 20 ng/kg IV	0.2470	± 36
PF-06671008 50 ng/kg IV	NA	± NA
PF-06671008 100 ng/kg IV	0.8471	± 51
PF-06671008 200 ng/kg IV	2.014	± 7
PF-06671008 300 ng/kg IV	NA	± NA
PF-06671008 200 ng/kg SC	NA	± NA
PF-06671008 200 ng/kg Prime and 300 ng/kg Maintenance IV	NA	± NA

Time to Reach Maximum Observed Serum Concentration (Tmax) of PF-06671008 Secondary · C1D1 0, 1, 2, 4, 8, 24, 48, 72 and 96 hrs post-dose, C2D1 0, 2, 4, 8, 24, 48, 72 and 96 hrs post-dose

Time for Maximum serum concentration (Tmax) of PF-06671008 was observed directly from data as time of first occurrence.

Cycle 1 Day 1

Group	Value	95% CI
PF-06671008 7.5 ng/kg IV	2.02	2.02 – 2.02
PF-06671008 20 ng/kg IV	4.05	2.00 – 4.08
PF-06671008 50 ng/kg IV	2.29	1.92 – 2.65
PF-06671008 100 ng/kg IV	2.07	2.00 – 4.10
PF-06671008 200 ng/kg IV	2.33	2.00 – 3.98
PF-06671008 300 ng/kg IV	2.17	2.05 – 3.63
PF-06671008 400 ng/kg IV	2.05	2.05 – 3.00
PF-06671008 200 ng/kg SC	50.5	8.12 – 92.9
PF-06671008 200 ng/kg Prime and 300 ng/kg Maintenance IV	1.92	1.92 – 1.92

Cycle 2 Day 1

Group	Value	95% CI
PF-06671008 7.5 ng/kg IV	2.12	2.12 – 2.12
PF-06671008 20 ng/kg IV	3.98	2.00 – 4.22
PF-06671008 50 ng/kg IV	3.90	3.90 – 3.90
PF-06671008 100 ng/kg IV	4.00	2.17 – 4.28
PF-06671008 200 ng/kg IV	2.09	1.92 – 2.17
PF-06671008 300 ng/kg IV	2.14	2.10 – 2.17
PF-06671008 200 ng/kg SC	24.6	23.4 – 25.7
PF-06671008 200 ng/kg Prime and 300 ng/kg Maintenance IV	1.98	1.98 – 1.98

Terminal Elimination Half-life (t1/2) of PF-06671008 Secondary · C1D1 0, 1, 2, 4, 8, 24, 48, 72 and 96 hrs post-dose, C2D1 0, 2, 4, 8, 24, 48, 72 and 96 hrs post-dose

Terminal elimination half-life (t1/2) of PF-06671008 was calculated as ln(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression. Arithmetic mean was not calculated if fewer than 3 participants had reportable parameter values.

Cycle 1 Day 1

Group	Value	95% CI
PF-06671008 50 ng/kg IV	NA	± NA
PF-06671008 100 ng/kg IV	31.77	± 7.6055
PF-06671008 200 ng/kg IV	35.30	± 5.4065
PF-06671008 300 ng/kg IV	NA	± NA
PF-06671008 400 ng/kg IV	NA	± NA
PF-06671008 200 ng/kg Prime and 300 ng/kg Maintenance IV	NA	± NA

Cycle 2 Day 1

Group	Value	95% CI
PF-06671008 100 ng/kg IV	NA	± NA
PF-06671008 200 ng/kg IV	NA	± NA
PF-06671008 300 ng/kg IV	NA	± NA

Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-06671008 Secondary · C1D1 0, 1, 2, 4, 8, 24, 48, 72 and 96 hrs post-dose, C2D1 0, 2, 4, 8, 24, 48, 72 and 96 hrs post-dose

Tau refers to the dosing interval, which was 1 week. Area under the concentration-time profile from time 0 to time tau (AUCtau) was determined using linear/log trapezoidal method. Geometric mean was not calculated if fewer than 3 participants had reportable parameter values.

Cycle 1 Day 1

Group	Value	95% CI
PF-06671008 1.5 ng/kg IV	NA	± NA
PF-06671008 7.5 ng/kg IV	NA	± NA
PF-06671008 20 ng/kg IV	5.252	± 25
PF-06671008 50 ng/kg IV	NA	± NA
PF-06671008 100 ng/kg IV	42.75	± 35
PF-06671008 200 ng/kg IV	87.31	± 29
PF-06671008 300 ng/kg IV	NA	± NA
PF-06671008 400 ng/kg IV	NA	± NA
PF-06671008 200 ng/kg SC	NA	± NA
PF-06671008 200 ng/kg Prime and 300 ng/kg Maintenance IV	NA	± NA

Cycle 2 Day 1

Group	Value	95% CI
PF-06671008 1.5 ng/kg IV	NA	± NA
PF-06671008 7.5 ng/kg IV	NA	± NA
PF-06671008 20 ng/kg IV	10.31	± 43
PF-06671008 50 ng/kg IV	NA	± NA
PF-06671008 100 ng/kg IV	NA	± NA
PF-06671008 200 ng/kg IV	79.17	± 36
PF-06671008 300 ng/kg IV	NA	± NA
PF-06671008 200 ng/kg SC	NA	± NA
PF-06671008 200 ng/kg Prime and 300 ng/kg Maintenance IV	NA	± NA

Area Under the Curve From Time 0 Extrapolated to Infinity Time (AUCinf) of PF-06671008 Secondary · C1D1 0, 1, 2, 4, 8, 24, 48, 72 and 96 hrs post-dose, C2D1 0, 2, 4, 8, 24, 48, 72 and 96 hrs post-dose

AUCinf was calculated as AUClast +(Clast\*/kel), where AUClast is area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\* is the predicted serum concentration at the last quantifiable time point estimated from the log-linear regression analysis, kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression. Geometric mean was not calculated if fewer than 3 participants had r

Cycle 1 Day 1

Group	Value	95% CI
PF-06671008 50 ng/kg IV	NA	± NA
PF-06671008 100 ng/kg IV	47.09	± 41
PF-06671008 200 ng/kg IV	90.35	± 19
PF-06671008 300 ng/kg IV	NA	± NA
PF-06671008 400 ng/kg IV	NA	± NA
PF-06671008 200 ng/kg Prime and 300 ng/kg Maintenance IV	NA	± NA

Systemic Clearance (CL) of PF-06671008 Secondary · C1D1 0, 1, 2, 4, 8, 24, 48, 72 and 96 hrs post-dose, C2D1 0, 2, 4, 8, 24, 48, 72 and 96 hrs post-dose

Systemic Clearance (CL) was calculated as dose/AUCinf, where AUCinf was area under the serum concentration-time profile from time 0 extrapolated to infinite time. This outcome measure only applies to IV arms. Geometric mean was not calculated if fewer than 3 participants had reportable parameter values.

Cycle 1 Day 1

Group	Value	95% CI
PF-06671008 50 ng/kg IV	NA	± NA
PF-06671008 100 ng/kg IV	2.191	± 47
PF-06671008 200 ng/kg IV	2.236	± 20
PF-06671008 300 ng/kg IV	NA	± NA
PF-06671008 400 ng/kg IV	NA	± NA
PF-06671008 200 ng/kg Prime and 300 ng/kg Maintenance IV	NA	± NA

Cycle 2 Day 1

Group	Value	95% CI
PF-06671008 7.5 ng/kg IV	NA	± NA
PF-06671008 20 ng/kg IV	1.954	± 40
PF-06671008 50 ng/kg IV	NA	± NA
PF-06671008 100 ng/kg IV	NA	± NA
PF-06671008 200 ng/kg IV	1.827	± 77
PF-06671008 300 ng/kg IV	NA	± NA
PF-06671008 200 ng/kg Prime and 300 ng/kg Maintenance IV	NA	± NA

Apparent Clearance (CL/F) of PF-06671008 Secondary · C1D1 0, 1, 2, 4, 8, 24, 48, 72 and 96 hrs post-dose, C2D1 0, 2, 4, 8, 24, 48, 72 and 96 hrs post-dose

Apparent Clearance (CL/F) was calculated as dose/AUCinf, where AUCinf was area under the serum concentration-time profile from time 0 extrapolated to infinite time. This outcome measure only applies to SC arm. Geometric mean was not calculated if fewer than 3 participants had reportable parameter values.

Cycle 2 Day 1

Group	Value	95% CI
PF-06671008 200 ng/kg SC	NA	± NA

Number of Participants With OR - Part 1 Secondary · Baseline and every 6 weeks for the first 6 months, then every 12 weeks until disease progression, unacceptable toxicity, or up to 24 months

Number of participants with OR based on assessment of CR or PR according to RECIST v1.1. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new l

Group	Value	95% CI
PF-06671008 1.5 ng/kg IV	0
PF-06671008 7.5 ng/kg IV	0
PF-06671008 20 ng/kg IV	0
PF-06671008 50 ng/kg IV	0
PF-06671008 100 ng/kg IV	0
PF-06671008 200 ng/kg IV	0
PF-06671008 300 ng/kg IV	0
PF-06671008 400 ng/kg IV	0
PF-06671008 200 ng/kg SC	0
PF-06671008 200 ng/kg Prime and 300 ng/kg Maintenance IV	0

Number of Participants With Anti Drug Antibodies (ADA) and Neutralizing Antibodies (NAb) Against PF-06671008 Secondary · C1D1 0 hrs, D15 0 hrs, and C2D1 0 hrs, and D1 0 hrs post additional dosings, up to 24 months

ADA against PF-06671008 in human serum samples was determined following a tiered approach using screening, confirmation, and titer/quantification by semi-quantitative enzyme linked immunosorbent assay (ELISA). Endpoint titer \>=1.18 was considered positive.

ADA

Group	Value	95% CI
PF-06671008 1.5 ng/kg IV	0
PF-06671008 7.5 ng/kg IV	0
PF-06671008 20 ng/kg IV	0
PF-06671008 50 ng/kg IV	0
PF-06671008 100 ng/kg IV	0
PF-06671008 200 ng/kg IV	0
PF-06671008 300 ng/kg IV	0
PF-06671008 400 ng/kg IV	0
PF-06671008 200 ng/kg SC	1
PF-06671008 200 ng/kg Prime and 300 ng/kg Maintenance IV	0

NAb

Group	Value	95% CI
PF-06671008 1.5 ng/kg IV	NA
PF-06671008 7.5 ng/kg IV	NA
PF-06671008 20 ng/kg IV	NA
PF-06671008 50 ng/kg IV	NA
PF-06671008 100 ng/kg IV	NA
PF-06671008 200 ng/kg IV	NA
PF-06671008 300 ng/kg IV	NA
PF-06671008 400 ng/kg IV	NA
PF-06671008 200 ng/kg SC	NA
PF-06671008 200 ng/kg Prime and 300 ng/kg Maintenance IV	NA

Adverse events — posted to ClinicalTrials.gov

Time frame: For all Adverse Events: Start of treatment to and including 28 days after the last dose. For All-Cause Mortality: Start of treatment to and including 28 days after the last dose + follow-up period (up to 2 years). Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

PF-06671008 1.5 ng/kg IV

Serious: 0/1 (0%)

Deaths: 1/1

PF-06671008 7.5 ng/kg IV

Serious: 1/2 (50%)

Deaths: 2/2

PF-06671008 20 ng/kg IV

Serious: 1/3 (33%)

Deaths: 1/3

PF-06671008 50 ng/kg IV

Serious: 2/2 (100%)

Deaths: 1/2

PF-06671008 100 ng/kg IV

Serious: 4/4 (100%)

Deaths: 4/4

PF-06671008 200 ng/kg IV

Serious: 4/5 (80%)

Deaths: 2/5

PF-06671008 300 ng/kg IV

Serious: 3/4 (75%)

Deaths: 1/4

PF-06671008 400 ng/kg IV

Serious: 2/3 (67%)

Deaths: 3/3

PF-06671008 200 ng/kg SC

Serious: 0/2 (0%)

Deaths: 1/2

PF-06671008 200 ng/kg Prime and 300 ng/kg Maintenance IV

Serious: 0/1 (0%)

Deaths: 0/1

Serious adverse events (6 terms)

Reaction	System	PF-06671008 1.5 ng/kg IV	PF-06671008 7.5 ng/kg IV	PF-06671008 20 ng/kg IV	PF-06671008 50 ng/kg IV	PF-06671008 100 ng/kg IV	PF-06671008 200 ng/kg IV	PF-06671008 300 ng/kg IV	PF-06671008 400 ng/kg IV	PF-06671008 200 ng/kg SC	PF-06671008 200 ng/kg Prim…
Cytokine release syndrome	Immune system disorders	—	—	—	—	—	—	—	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—
Neoplasm progression	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—	—	—	—	—	—	—	—
Rectal adenocarcinoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—	—	—	—	—	—	—	—
Pneumonitis	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—

Other adverse events (95 terms — click to expand)

Reaction	System	PF-06671008 1.5 ng/kg IV	PF-06671008 7.5 ng/kg IV	PF-06671008 20 ng/kg IV	PF-06671008 50 ng/kg IV	PF-06671008 100 ng/kg IV	PF-06671008 200 ng/kg IV	PF-06671008 300 ng/kg IV	PF-06671008 400 ng/kg IV	PF-06671008 200 ng/kg SC	PF-06671008 200 ng/kg Prim…
Fatigue	General disorders	—	—	—	—	—	—	—	—	—	—
Pyrexia	General disorders	—	—	—	—	—	—	—	—	—	—
Cytokine release syndrome	Immune system disorders	—	—	—	—	—	—	—	—	—	—
Lymphocyte count decreased	Investigations	—	—	—	—	—	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—
Oedema peripheral	General disorders	—	—	—	—	—	—	—	—	—	—
Platelet count decreased	Investigations	—	—	—	—	—	—	—	—	—	—
White blood cell count decreased	Investigations	—	—	—	—	—	—	—	—	—	—
Decreased appetite	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—	—
Hypophosphataemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—	—
Myalgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—	—
Headache	Nervous system disorders	—	—	—	—	—	—	—	—	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—
Pruritus	Skin and subcutaneous tissue disorders	—	—	—	—	—	—	—	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—
Neutropenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—
Palpitations	Cardiac disorders	—	—	—	—	—	—	—	—	—	—
Sinus arrhythmia	Cardiac disorders	—	—	—	—	—	—	—	—	—	—
Tachycardia	Cardiac disorders	—	—	—	—	—	—	—	—	—	—
Ventricular arrhythmia	Cardiac disorders	—	—	—	—	—	—	—	—	—	—
Tinnitus	Ear and labyrinth disorders	—	—	—	—	—	—	—	—	—	—
Vertigo	Ear and labyrinth disorders	—	—	—	—	—	—	—	—	—	—
Periorbital oedema	Eye disorders	—	—	—	—	—	—	—	—	—	—
Vision blurred	Eye disorders	—	—	—	—	—	—	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—
Abdominal pain upper	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—
Aphthous ulcer	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—
Constipation	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—
Dry mouth	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—
Dyspepsia	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—
Dysphagia	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—
Gastrooesophageal reflux disease	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—
Pancreatitis	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—
Stomatitis	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—
Chest pain	General disorders	—	—	—	—	—	—	—	—	—	—
Chills	General disorders	—	—	—	—	—	—	—	—	—	—
Infusion site extravasation	General disorders	—	—	—	—	—	—	—	—	—	—
Injection site erythema	General disorders	—	—	—	—	—	—	—	—	—	—

Most-reported serious reactions: Cytokine release syndrome, Anaemia, Diarrhoea, Neoplasm progression, Rectal adenocarcinoma, Pneumonitis.

Data from ClinicalTrials.gov NCT02659631 adverse events section.

Sponsor's own description

The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of PF-06671008 in patients with advanced solid tumors with the potential to have P-cadherin expression. The study will then expand to look at the selected dose in patients with P-cadherin expressing TNBC, CRC or NSCLC.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Bispecific Antibodies: From Research to Clinical Application.
Ma J, Mo Y, Tang M, Shen J, et al · · 2021 · cited 199× · PMID 34025638 · DOI 10.3389/fimmu.2021.626616
Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics.
Runcie K, Budman DR, John V, Seetharamu N. · · 2018 · cited 120× · PMID 30249178 · DOI 10.1186/s10020-018-0051-4
T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.
Wu Z, Cheung NV. · · 2018 · cited 115× · PMID 28834699 · DOI 10.1016/j.pharmthera.2017.08.005
Overcoming the challenges associated with CD3+ T-cell redirection in cancer.
Singh A, Dees S, Grewal IS. · · 2021 · cited 82× · PMID 33469153 · DOI 10.1038/s41416-020-01225-5
Biology drives the discovery of bispecific antibodies as innovative therapeutics.
Nie S, Wang Z, Moscoso-Castro M, D'Souza P, et al · · 2020 · cited 79× · PMID 33928225 · DOI 10.1093/abt/tbaa003
Emerging therapeutic agents for lung cancer.
Dholaria B, Hammond W, Shreders A, Lou Y. · · 2016 · cited 66× · PMID 27938382 · DOI 10.1186/s13045-016-0365-z
Bispecific antibodies in cancer therapy: Target selection and regulatory requirements.
Sun Y, Yu X, Wang X, Yuan K, et al · · 2023 · cited 62× · PMID 37719370 · DOI 10.1016/j.apsb.2023.05.023
A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DART<sup>®</sup>.
Betts A, Haddish-Berhane N, Shah DK, van der Graaf PH, et al · · 2019 · cited 60× · PMID 31119428 · DOI 10.1208/s12248-019-0332-z

Verify or expand the search:

Other recruiting trials for Neoplasms

Currently open trials in the same condition.

NCT07438782 — First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combinatio · Phase 1 · recruiting
NCT07382817 — Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms · Phase 1 · recruiting
NCT07277270 — A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tum · Phase 1 · recruiting
NCT07257640 — IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia · Phase 1 · recruiting
NCT07213609 — A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer · Phase 1, PHASE2 · recruiting

Other Pfizer trials

Trials by the same sponsor.

NCT04982848 — Korea Post Marketing Surveillance (PMS) Study of Talzenna® · not yet recruiting
NCT06873191 — A Study to Learn More About Tukysa Once it is Out in the Korean Market · not yet recruiting
NCT07497854 — A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea · not yet recruiting
NCT06507904 — A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Anta · Phase 1 · not yet recruiting
NCT06864585 — A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02659631 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pfizer
Last refreshed: 6 May 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02659631.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT02659631

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Adverse events — posted to ClinicalTrials.gov

Serious adverse events (6 terms)

Sponsor's own description

Publications & conference data

Related trials

Other recruiting trials for Neoplasms

Other Pfizer trials

Verify against primary sources